Matt Frankel, The Motley Fool

Mon, May 19, 2025, 6:04 AM3 min read

• Digital medical platform leader Doximity reported better-than-expected results on the top and bottom lines.

• Free cash flow grew by more than 50% year over year, and margins are stellar.

• Doximity's guidance shows revenue growth slowing sharply in the new fiscal year.

• These 10 stocks could mint the next wave of millionaires ›

Here's our initial take on Doximity's (NYSE: DOCS) financial report.

At first glance, Doximity's earnings report looked rather strong. In its fiscal fourth quarter (ended March 31), the digital medical platform provider reported 17% year-over-year revenue growth, which handily beat analysts' expectations. On the bottom line, the company's $0.38 adjusted earnings per share (EPS) was significantly greater than the $0.27 analysts had expected.

Beyond the headline numbers, Doximity's earnings report was generally solid. Free cash flow increased by 56% year over year, and for the full fiscal year, the company reported a stellar 47% free cash flow margin.

The report wasn't all good news, however. Doximity's guidance wasn't quite what analysts had been looking for. For the first quarter, Doximity is guiding for $139.5 million in revenue at the midpoint of its range. Not only would that represent 1% sequential growth, but it also fell far short of analysts' expectations of $143 million.

For the full year, it wasn't much better. The consensus called for $635 million in revenue for the fiscal year ending in March 2026, and Doximity guided for $625 million at the midpoint. This would translate into 9.6% year-over-year revenue growth, much more of a deceleration than analysts expected.

Unsurprisingly, the initial reaction to Doximity's earnings was negative. While the fiscal fourth-quarter results were impressive, giving disappointing forward guidance is a pretty certain recipe for a negative move in a stock.

As of 3:30 p.m. ET on May 16, the day after the earnings announcement, Doximity was trading lower by about 10%. After spiking higher earlier in the year, the stock is now at about 37% below its highs.

Doximity still sees a massive opportunity ahead of it, estimating its addressable market at about $18.5 billion. Based on trailing-12-month revenue, it currently has about 3% of this amount. With slower growth projected going forward, it's a question of whether Doximity is having trouble maintaining its momentum now that about 80% of U.S. physicians already use the platform or if management is simply being cautious in a weakening economic climate.